<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01711918</url>
  </required_header>
  <id_info>
    <org_study_id>Domperidone</org_study_id>
    <nct_id>NCT01711918</nct_id>
  </id_info>
  <brief_title>Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis</brief_title>
  <official_title>Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ron Schey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide oral domperidone to patients between the ages of 18 and 60 years of age, according
      to the investigator's judgment, a prokinetic effect is needed for the relief of severe
      gastroparesis. We have defined severe gastroparesis as 1) positive gastric emptying
      scintigraphy (more than 10% residue at 4 hours), 2) nausea, 3) early satiety, 4) abdominal
      pain. We will recruit patients for two years and the patients will be given domperidone for
      up to two years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of Overall Symptoms Based on Likert Scale</measure>
    <time_frame>Baseline and End of study (2 years or last visit if patient withdraws)</time_frame>
    <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Nausea Based on Likert Scale</measure>
    <time_frame>Baseline and End of study (2 years or last visit if patient withdraws)</time_frame>
    <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Vomiting Based on Likert Scale</measure>
    <time_frame>Baseline and End of study (2 years or last visit if patient withdraws)</time_frame>
    <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Abdominal Bloating or Distention Based on Likert Scale</measure>
    <time_frame>Baseline and End of study (2 years or last visit if patient withdraws)</time_frame>
    <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Premature Abdominal Fullness After Meals Based on Likert Scale</measure>
    <time_frame>Baseline and End of study (2 years or last visit if patient withdraws)</time_frame>
    <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Patients With Gastroparesis Who Have Failed Standard Therapy</condition>
  <arm_group>
    <arm_group_label>Domperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will received domperidone at a dose of 10mg given up to three times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>oral tablet; dose is 10mg per tablet given up to 3 times daily.</description>
    <arm_group_label>Domperidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female

          2. Age 18 - 60

          3. Symptoms or manifestation secondary to gastroparesis such as vomiting, nausea, the
             feeling you are full after you start eating, and abdominal pain.

          4. Subjects must have a comprehensive evaluation to eliminate other causes of their
             symptoms which includes gastric emptying scintigraphy, esophagogastroduodenoscopy
             (EGD), and the patient's subjective symptoms.

          5. Subject has signed informed consent for the administration of domperidone that informs
             the patient of potential adverse events

          6. Female subjects must be:

               1. surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal
                  ligation)

               2. if sexual active, practicing an effective method of birth control such as
                  hormonal prescription oral contraceptives, progesterone implants or injections,
                  contraceptive patch, intrauterine device, or maintenance of a monogamous
                  relationship with a male partner who has been surgically sterilized by vasectomy.
                  A double barrier method such as condoms, diaphragms, or cervical caps with
                  spermicidal foam, cream, or gel may be used as a method of birth control

        Exclusion Criteria:

          1. History of, or current, arrhythmias including ventricular tachycardia, ventricular
             fibrillation, atrial fibrilation and Torsade des Pointes, subjects with minor forms of
             ectopy (PACs) are not necessarily excluded

          2. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged
             QTc (QTC&gt;450 milliseconds for males, QTc&gt;470 milliseconds for females)

          3. Clinically significant electrolyte disorders

          4. Gastrointestinal hemmorrhage or obstruction

          5. Presence of a prolactinoma (prolactin-releasing pituitary tumor)

          6. Pregnant or breast feeding female

          7. Known allergy to domperidone The following medications are prohibited during the
             study: antidepressants: doxepin, clomipramine, amopxapine, trazodone, venlafaxine,
             nefazodone, fluvoxamine, paroxetine, fluoxetine, sertraline, amitriptyline,
             maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline;
             anti-psychotics: haloperidol, chlorpromazine, chlorpromazine pimozide, sertindole,
             quetiapine, mesoridazine, perphenazine, lfluphenazine, promazine, trifluoperazine;
             anti-emetics: prochlorperazine, thioridazine, promethazine, mesoridazine,
             theiethylperazine, perphazine, dolasetron, dronabinol, droperidol; anti-infective
             agents: erythromycin, clarithromycin, troleandomycin, norfloxcin, quinine sulfate,
             quinupristin and dalfopristin, pentamidine, sparfloxacin, grepafloxacin, azithromycin,
             ofloxacin, levofloxacin; anti-fungal agents: fluconazole, itraconazole, ketoconazole,
             miconazole, terconazole, ticonazole, butaconazole; antivirals: foscarnet; protease
             inhibitors: indinavir, amprenavir, ritonavir, nelfinavir, squinavir;
             antihypertensives: nicardipine, isradipine, moexipril/HCTZ; calcium channel blockers:
             verapamil, diltiazem, deltiazem/enalapril, verapamil/trandolapril, tocainide,
             bepridil; anti-arrhythmics: disopyramide, quinidine, procainamide, flecainide,
             sotalol, bretylium, amiodarone, ibutilide, moricizine; diueretics: bumetanide,
             furosemide, torsemide, etharcrynic acid, chlorothiazide, indapamide; antilipemics:
             probucol, bepridil, mibefradil; hematological agents: cilostazol; respiratory agents:
             zafirlukast, salmetrol; gastrointestinal agents: cimetidine, cisapride; antidiarrheal:
             octreotide; antihistamines: azelastine, clemastine; migraine treatment: naratriptan,
             sumatriptan, zolmitriptan; antimalarial: halofantrine; muscle relaxants: tizanidine;
             narcotic dependence: levomethadyl; miscellaneous: tamoxifen, warfarin, phenytoin,
             ziprasidone, risperidone, formoterol fumarate, sildenafil; drugs that prolong the QT
             Interval: albuterol, alfuzosin, amantadine, amisulpride, amphetamine, arsenic
             trioxide, astemizole, atazanavir, atomoxetine, chloral hydrate, chloroquine,
             ciprofloxacin, citalopram, clozapine, cocaine, dexmethylphenidate, diphenhydramine,
             dobutamine, dofetilide, dopamine, dronedarone, ephedrine, epinephrine, eribulin,
             escitalopram, famotidine, felbamate, fenfluramine, fingolimod, fosphenytoin,
             galantamine, gatifloxacin, gemifloxacin, granisetron, iloperidone, isoproterenol,
             lapatinib, levalbuterol, lisdexamfetamine, lithium, metaproterenol, methadone,
             methylphenidate, midodrine, moxifloxacin, nilotinib, norepinephrine, ondansetron,
             oxytocin, paliperidone, perflutren lipid microspheres, phentermine, phenylephrine,
             phenylpropanolamine, protriptyline, pseudoephedrine, ranolazine, ritodrine,
             toxithromycin, sibutramine, solifenacin, sunitinib, tacrolimus, telithromycin,
             terbutaline, terfenadine, tolterodine, trimethoprim-sulfa, vandetanib, vardenafil,
             voriconazole.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2012</study_first_submitted>
  <study_first_submitted_qc>October 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2012</study_first_posted>
  <results_first_submitted>October 24, 2016</results_first_submitted>
  <results_first_submitted_qc>October 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2016</results_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Ron Schey</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>gastroparesis</keyword>
  <keyword>domperidone</keyword>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Domperidone</title>
          <description>Participants will received domperidone at a dose of 10mg given up to three times per day
Domperidone: oral tablet; dose is 10mg per tablet given up to 3 times daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Domperidone</title>
          <description>Participants will received domperidone at a dose of 10mg given up to three times per day
Domperidone: oral tablet; dose is 10mg per tablet given up to 3 times daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement of Overall Symptoms Based on Likert Scale</title>
        <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
        <time_frame>Baseline and End of study (2 years or last visit if patient withdraws)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Domperidone</title>
            <description>Participants will received domperidone at a dose of 10mg given up to three times per day
Domperidone: oral tablet; dose is 10mg per tablet given up to 3 times daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Overall Symptoms Based on Likert Scale</title>
          <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Nausea Based on Likert Scale</title>
        <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
        <time_frame>Baseline and End of study (2 years or last visit if patient withdraws)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Domperidone</title>
            <description>Participants will received domperidone at a dose of 10mg given up to three times per day
Domperidone: oral tablet; dose is 10mg per tablet given up to 3 times daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Nausea Based on Likert Scale</title>
          <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Vomiting Based on Likert Scale</title>
        <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
        <time_frame>Baseline and End of study (2 years or last visit if patient withdraws)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Domperidone</title>
            <description>Participants will received domperidone at a dose of 10mg given up to three times per day
Domperidone: oral tablet; dose is 10mg per tablet given up to 3 times daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Vomiting Based on Likert Scale</title>
          <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Abdominal Bloating or Distention Based on Likert Scale</title>
        <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
        <time_frame>Baseline and End of study (2 years or last visit if patient withdraws)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Domperidone</title>
            <description>Participants will received domperidone at a dose of 10mg given up to three times per day
Domperidone: oral tablet; dose is 10mg per tablet given up to 3 times daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Abdominal Bloating or Distention Based on Likert Scale</title>
          <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Premature Abdominal Fullness After Meals Based on Likert Scale</title>
        <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
        <time_frame>Baseline and End of study (2 years or last visit if patient withdraws)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Domperidone</title>
            <description>Participants will received domperidone at a dose of 10mg given up to three times per day
Domperidone: oral tablet; dose is 10mg per tablet given up to 3 times daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Premature Abdominal Fullness After Meals Based on Likert Scale</title>
          <description>A subject will be considered a responder, if they report on a 6 point Likert scale that when compared to baseline, their symptoms are either 'somewhat better or markedly better'.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Domperidone</title>
          <description>Participants will received domperidone at a dose of 10mg given up to three times per day
Domperidone: oral tablet; dose is 10mg per tablet given up to 3 times daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Partial Bowel Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Shaking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hand Tingling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured Right Ovarian Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ron Schey</name_or_title>
      <organization>University of Iowa</organization>
      <phone>3193849756</phone>
      <email>ron-schey@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

